ClinicalTrials.gg
RecruitingNCT07582159Updated Nov 6, 2026

Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A Phase 2 interventional study of Acalabrutinib and Biospecimen Collection in Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Small Lymphocytic Lymphoma, sponsored by City of Hope Medical Center. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by City of Hope Medical Center · Phase 2, Interventional, and Treatment

How we know

Updated Nov 6, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 28 under way, 6 of them phase 3. acalabrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Planned enrollment
28th of 39
35 · median 61
Started
2026
with 1 other
Phase 2
22 of 39
8 open now
Primary completion
2029-04
later than 26 of 27 live
Registered
39th of 39
by date
Lead sponsor
2 of 39
City of Hope Medical Center

Among the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 28th largest by planned enrollment, is one of 2 that started in 2026, is one of 22 in phase 2, reaches primary completion later than 26 of the 27 other live ones, and was the 39th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing acalabrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This phase II trial tests the safety, side effects and how well giving tafasitamab with acalabrutinib and venetoclax works for the treatment of chronic lymphocytic leukemia (CLL)/small cell lymphoma (SLL). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Tafasitamab is a monoclonal antibody that binds to CD19 antigen which is found on the surface of most B cells (a type of white blood cell) and some lymphoma cells. This may help the immune system kill cancer cells. Acalabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cell (a type of white blood cells) cancers such as mantle cell lymphoma at abnormal levels. This may help keep cancer cells from growing and spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving tafasitamab with acalabrutinib and venetoclax may be safe and effective for treating patients with CLL/SLL.

Read the detailed description

PRIMARY OBJECTIVES:

I. To evaluate the safety and tolerability of tafasitamab in combination with acalabrutinib and venetoclax, as assessed by unacceptable toxicity, in patients with previously untreated CLL/SLL. (Safety lead-in) II. To evaluate efficacy of tafasitamab in combination with acalabrutinib and venetoclax, as assessed by complete response (CR) with undetectable minimal residual disease (MRD) by flow cytometry in peripheral blood, in patients with previously untreated CLL/SLL. (Phase 2)

SECONDARY OBJECTIVES:

I. To evaluate the safety and tolerability of tafasitamab in combination with acalabrutinib and venetoclax, as assessed by all toxicities.

II. To evaluate efficacy of tafasitamab in combination with acalabrutinib and venetoclax, as assessed by overall response rate (ORR), progression-free survival (PFS), duration of response (DOR) and overall survival (OS).

EXPLORATORY OBJECTIVES:

I. To evaluate MRD status in the bone marrow by flow cytometry and by Clonoseq in patients with previously untreated CLL/SLL treated with tafasitamab in combination with acalabrutinib and venetoclax.

II. To explore the association between the potential risk factors (including IGHV mutation, del17p/TP53 mutation, complex cytogenetics) and the clinical outcomes in patients with previously untreated CLL/SLL treated with tafasitamab in combination with acalabrutinib and venetoclax.

OUTLINE:

CYCLES 1 AND 2: Patients receive acalabrutinib orally (PO) twice daily (BID) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

CYCLES 3-5: Patients receive acalabrutinib PO BID, venetoclax PO once daily (QD) on days 1-28, and tafasitamab intravenously (IV) over 1.5-2.5 hours on days 1, 8, 15 and 22 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

CYCLES 6-8: Patients receive acalabrutinib PO BID, venetoclax PO QD on days 1-28, and tafasitamab IV over 1.5-2.5 hours on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

CYCLES 9-14: Patients receive acalabrutinib PO BID and venetoclax PO QD on days 1-28 and tafasitamab IV over 1.5-2.5 hours on day 1 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Patients undergo urine sample collection and bone marrow biopsy at screening, as well as computed tomography (CT) scan or positron emission tomography (PET)-CT scan and blood sample collection throughout the study.

After completion of study treatment, patients are followed up every 3 months until progressive disease, then every 6 months, up to 3 years.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  • Small Lymphocytic Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented of the participant and/or legally authorized representative.

    • Assent, when appropriate, will be obtained per institutional guidelines
  • Agreement to allow the use of from diagnostic tumor biopsies

    • If unavailable, exceptions may be granted with study principal investigator (PI) approval
  • Age: ≥ 18 years
  • (ECOG) ≤ 2
  • Histologically or flow cytometry confirmed diagnosis of B-CLL/SLL as documented by medical records and with histology based on criteria established by the World Health Organization (WHO)
  • No prior treatment for CLL/SLL, except and/or rituximab to treat complications
  • Active disease meeting criteria for requiring treatment per the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 guidelines

    • A minimum of any one of the following constitutional symptoms:

      • Unintentional weight loss > 10% within the previous 6 months prior to screening.
      • Extreme fatigue (unable to work or perform usual activities).
      • Fevers of greater than 100.5°F for ≥ 2 weeks without evidence of infection.
      • Night sweats without evidence of infection.
    • Evidence of progressive marrow failure as manifested by the development of, or worsening of anemia or thrombocytopenia.
    • Massive (i.e., > 6 cm below the left costal margin), progressive or symptomatic splenomegaly.
    • Massive nodes or clusters (i.e., > 10 cm in longest diameter) or progressive lymphadenopathy.
    • Progressive lymphocytosis with an increase of > 50% over a 2-month period, or an anticipated doubling time of less than 6 months.
    • Autoimmune anemia or thrombocytopenia that is poorly responsive to corticosteroids.
    • Symptomatic or functional extranodal involvement (eg, skin, kidney, lung, spine)
  • Participant must be able to swallow tablets or capsules. A participant with any gastrointestinal disease that would impair ability to swallow, retain, or absorb drug is not eligible
  • (ANC) ≥ 500/mm\^3
  • ≥ 30,000/mm\^3
  • Total ≤ 2 X (ULN) (unless has Gilbert's disease or compensated hemolysis directly attributable to CLL)
  • (AST) ≤ 2.5 x ULN
  • Alanine aminotransferase ≤ 2.5 x ULN
  • of ≥ 30 mL/min per 24 hour urine test or the Cockcroft-Gault formula
  • If not receiving anticoagulants: (INR) OR Prothrombin (PT) ≤ 1.5 x ULN. If on anticoagulant therapy: PT must be within therapeutic range of intended use of anticoagulants
  • If not receiving anticoagulants: Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 x ULN. If on anticoagulant therapy: aPTT must be within therapeutic range of intended use of anticoagulants
  • If seropositive for , virus (HCV) or virus (HBV), nucleic acid quantitation must be performed. Viral load must be undetectable. HIV-infected patients on active anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
  • Women of (WOCBP): negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Agreement by females and males of childbearing potential* to use an effective method of or abstain from heterosexual activity for the course of the study and after completion of study treatment as described below separately for males and females.

    • Female participants must remain abstinent or use contraceptive methods with a failure rate of \< 1% per year during the treatment period and for at least 2 days after the final dose of acalabrutinib, 30 days after the last dose of venetoclax, and 3 months after the final dose of tafasitamab, whichever is longer. Women must refrain from donating eggs during this same period.

      • Examples of contraceptive methods with a failure rate of \< 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices.
      • Hormonal contraceptive methods must be supplemented by a barrier method.
    • For male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agree to refrain from donating sperm, as defined below:

      • With a female partner of childbearing potential or pregnant female partners, male participants must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of \< 1% per year during the treatment period and for at least 2 days after the final dose of acalabrutinib, 90 days after the last dose of venetoclax, and 3 months after the final dose of tafasitamab, whichever is longer. Male participants must refrain from donating sperm during this same period.
    • The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the individual. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.
    • A woman is considered of childbearing potential, ie, fertile, following menarche and until becoming unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. Contraception methods include the following:

      • Combined (estrogen- and progestogen- containing) hormonal contraception associated with the inhibition of ovulation

        • Oral, intravaginal, or transdermal
      • Progestogen-only hormonal contraception associated with the inhibition of ovulation

        • Oral, injectable, implantable
      • An intrauterine device
      • Intrauterine hormone-releasing system
      • Bilateral tubal occlusion Vasectomized partner (provided that the vasectomized partner is the sole sexual partner of the woman of childbearing potential study participant and that the vasectomized partner has received medical assessment of surgical success)
      • Sexual abstinence (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment, starting the day prior to first dose of study drug, for the duration of the study, and for ≥ 90 days after the last dose of zanubrutinib or ibrutinib. Total sexual abstinence should only be used as a contraceptive method if it is in line with the patients' usual and preferred lifestyle. Of note, barrier contraception (including male and female condoms with or without spermicide) is not considered a highly effective method of contraception, and, if used, this method must be used in combination with another acceptable method listed above. If patient is using hormonal contraceptives such as birth control pills or devices, a barrier method of contraception (eg, condoms) must also be used. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle-stimulating hormone level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single follicle-stimulating hormone measurement is insufficient

Exclusion criteria

Exclusion Criteria:

  • Chronic use of in excess of 20 mg/day prednisone or its equivalent
  • Major surgery (under general anesthesia) within 30 days prior to therapy
  • Uncontrolled coagulopathy or bleeding disorder. Direct oral anticoagulants are allowed
  • Use of moderate or strong cytochrome P450 3A4 () inducer within 2 weeks of the first day of study therapy. CYP3A inhibitors are allowed
  • Exposure to vaccination with within 30 days prior to cycle (C) 1 day (D) 1, or anticipated need for such vaccination during treatment
  • History of prior except:

    • Malignancy treated with curative intent and no known active disease present for ≥ 2 years prior to initiation of therapy on current study;
    • Adequately treated non-melanoma skin cancer or lentigo maligna (melanoma in situ) without evidence of disease
    • Adequately treated in situ carcinomas (e.g., cervical, esophageal, etc.) without evidence of disease;
    • Asymptomatic prostate cancer managed with "watch and wait" strategy;
  • Uncontrolled immune hemolysis or thrombocytopenia (positive direct antiglobulin test in absence of hemolysis or history of immune-mediated cytopenias are not exclusions)
  • Active infection
  • Known positive test result for (HCV antibody serology testing) and a positive test result for HCV ribonucleic acid (RNA). Participants with positive serology are eligible in case of negative HCV RNA test results
  • Known active virus (HBV) or hepatitis C virus (HCV) infection. Patients with past HBV infection (defined as negative hepatitis B surface antigen (HBsAg) and positive hepatitis B core antibody [HBcAb]) are eligible if HBV deoxyribonucleic acid (DNA) is undetectable. Patients who are positive for HCV antibody are eligible if polymerase chain reaction (PCR) is negative for HCV RNA
  • Known active (HIV) infection. Subjects who have an undetectable or unquantifiable HIV viral load with > 200 and are on highly active antiretroviral therapy (HAART) medication are allowed. Testing to be done only in patients suspected of having infections or exposures
  • Females only: Pregnant or breastfeeding
  • Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Treatment (Tafasitamab, acalabrutinib, venetoclax)

    See Detailed Description

    Drug: Acalabrutinib · Procedure: Biospecimen Collection · Procedure: Bone Marrow Biopsy · Procedure: Computed Tomography · Procedure: Positron Emission Tomography · Biological: Tafasitamab · Drug: Venetoclax

Interventions

  • Given PO

    Also known as: ACP 196, ACP-196, ACP196, Bruton Tyrosine Kinase Inhibitor ACP-196

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy

    Also known as: Biopsy of Bone Marrow, Biopsy, Bone Marrow

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • ProcedurePositron Emission Tomography

    Undergo PET scan

    Also known as: Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT

  • BiologicalTafasitamab

    Given IV

    Also known as: Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR 00208, MOR 208, MOR-00208, MOR-208, MOR00208, MOR208, Tafasitamab-cxix, XmAb-5574, XmAb5574

  • Given PO

    Also known as: ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto

06

What researchers measure

Primary outcomes

  1. Incidence of unacceptable toxicity

    Defined as toxicities deemed related (possibly, probably or definitely) to the study drugs.

    Time frame: From cycle 1 day 1 to completion of cycle 4 (cycle length = 28 days)

  2. Complete response with undetectable minimal residual disease (MRD)

    Complete response is defined by International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria; undetectable is defined as \< 10\^-4 CLL cells in the peripheral blood by flow cytometry. Will be estimated by the proportion of evaluable patients achieving that endpoint, along with the 95% exact binomial confidence interval.

    Time frame: At the end of therapy after a minimum of 4 cycles

Secondary outcomes

  1. Overall response

    Defined as achieving complete response (CR) or partial response (PR) according to iwCLL 2018 guidelines on this study before any documented disease progression or any subsequent treatment. Will be estimated by the proportion of evaluable patients achieving that endpoint, along with the 95% exact binomial confidence interval.

    Time frame: Up to 3 years

  2. Progression free survival

    Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval of the PFS estimate at specific timepoint will be constructed based on log-log transformation. Median PFS will be estimated when available.

    Time frame: From start of protocol treatment to disease relapse/progression or death due to any cause, up to 3 years

  3. Duration of response

    Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval of the DOR estimate at specific timepoint will be constructed based on log-log transformation. Median DOR will be estimated when available.

    Time frame: From the first achievement of CR or PR on this study to disease progression/relapse or death due to any cause, up to 3 years

  4. Overall survival

    Will be estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error; 95% confidence interval of the OS estimate at specific timepoint will be constructed based on log-log transformation. Median OS will be estimated when available.

    Time frame: From the start of protocol treatment to death due to any cause, up to 3 years

  5. Incidence of adverse events

    Grading of platelet, hemoglobin, and neutrophils toxicities will be conducted according to iwCLL 2018 criteria. Grading of all other toxicities will be according to National Cancer Institute Common Terminology Criteria for Adverse Events version 6.0.

    Time frame: Up to 3 years

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Apr 2029, 27 months later.

Of 207 non-industry phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's planned 27 months is below that.

Counting every sponsor, half of 248 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2026
First posted
May 12, 2026
StartEst.
Dec 19, 2026
Primary completionEst.
Apr 14, 2029
CompletionEst.
Apr 14, 2029
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • City of Hope Medical Center · Duarte, United Statesno status→Recruiting
  • City of Hope at Irvine Lennar · Irvine, United Statesno status→Recruiting
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • City of Hope Medical Center · Duarte, United Statesno status→Recruiting
    • City of Hope at Irvine Lennar · Irvine, United Statesno status→Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07582159
Responsible party
Sponsor
First posted
May 12, 2026
Start date
Dec 19, 2026 (estimated)
Primary completion
Apr 14, 2029 (estimated)
Completion
Apr 14, 2029 (estimated)
Last update
Nov 6, 2026

Study contacts

Benjamin M Heyman
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acalabrutinib · Tafasitamab · Venetoclax

Start the discussion